aiv infeqcia/SidsiT avadmyofTa mkurnaloba da movla (klinikuri ...

122. Koval CE et al. Immune reconstitution syndrome after successful treatment of Pneumocystis carinii
pneumonia in a man with human immunodeficiency virus type 1 infection. Clinical Infectious Diseases,
2002, 35(4):491–493.
123. Sande MA, Eliopoulos GM. The Sanford guide to HIV/AIDS therapy, 13th ed. Hyde Park, VT,
Antimicrobial Therapy, 2004.
124. Gilbert DN, Moellering RC, Eliopoulos GM. The Sanford guide to antimicrobial therapy, 35th ed.
Hyde Park, VT, Antimicrobial Therapy, 2005.
125. Antoniu T, Tseng AL. Interactions between recreational drugs and antiretroviral agents. The Annals of
Pharmacotherapy, 2002, 36(10):1598–1613.
126. WHO/EURO report of the technical consultation on clinical staging of HIV/AIDS and HIV/AIDS case
definition for surveillance. Copenhagen, WHO Regional Office for Europe, 2005 (http://www.euro.
who.int/document/E87956.pdf, accessed 5 April 2006).
127. 2006 antiretroviral drug guide. IAPAC Monthly, 2006, 12 Suppl. 1 (http://www.iapac.org/home.
asppid=7288, accessed 11 September 2006).
128. Liu H et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Annals
of Internal Medicine, 2001, 134(10):968–977.
129. Bangsberg DR et al. Provider assessment of adherence to HIV antiretroviral therapy. Journal of Acquired
Immune Deficiency Syndromes, 2001, 26(5):435–442.
130. Hugen PW et al. Assessment of adherence to HIV protease inhibitors: comparison and combination of
various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic
drug monitoring. Journal of Acquired Immune Deficiency Syndromes, 2002, 30(3):324–334.
131. Paterson DL et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.
Annals of Internal Medicine, 2000, 133(1):21–30.
132. Parienti JJ et al. The pills identification test: a tool to assess adherence to antiretroviral therapy. JAMA,
2001, 285(4):412.
133. Descamps D et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from
a trial of induction-maintenance therapy. JAMA, 2000, 283(2):205–11.
134. Havlir DV et al. Drug susceptibility in HIV infection after viral rebound in patients receiving
indinavircontaining
regimens. JAMA, 2000, 283(2):229–234.
135. Vingerhoets J et al. Effect of baseline resistance on the virologic response to a novel NNRTI, TMC 125,
in patients with extensive NNRTI and PI resistance: analysis of study TMC 125–233. 13th Annual Conference
on Retroviruses and Opportunistic Infections (CROI), Denver, 5–8 February 2006 (Abstract
154).
136. De Meyer et al. Effect of baseline susceptibility and on-treatment mutations on TMC 114 and control
PI efficacy: preliminary analysis of data from PI-experienced patients from POWER 1 and POWER 2.
13th Annual Conference on Retroviruses and Opportunistic Infections (CROI), Denver, 5–8 February
2006 (Abstract 157).
72